Overview
Stereotaxis Q3 2025 revenue declines to $7.5 mln, system revenue significantly lower
Company reports Q3 net loss of $6.5 mln, slightly wider than last year
Stereotaxis expects Q4 revenue to exceed $9 mln, driven by new product launches
Outlook
Stereotaxis expects Q4 revenue to exceed $9 mln, with system revenue around $3 mln
Company anticipates annual revenue growth of over 20% for 2025
Stereotaxis projects quarterly revenue to surpass $10 mln in 2026
Result Drivers
NEW PRODUCT LAUNCHES - MAGiC Sweep and MAGiC ablation catheter contributed to recurring revenue growth
REGULATORY ADVANCEMENTS - FDA clearance for GenesisX and CE Mark for Synchrony expected to drive future growth
CATALOG EXPANSION - Ongoing development of catheter innovations to boost commercial results
Key Details
Metric | Beat/Miss | Actual | Consensus Estimate |
Q3 Revenue | $7.46 mln | ||
Q3 EPS | -$0.07 | ||
Q3 Net Income | -$6.46 mln | ||
Q3 Operating Expenses | $10.66 mln | ||
Q3 Operating Income | -$6.56 mln |
Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 4 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"
The average consensus recommendation for the advanced medical equipment & technology peer group is "buy"
Wall Street's median 12-month price target for Stereotaxis Inc is $4.00, about 30.1% above its November 10 closing price of $2.80
Press Release: ID:nGNXbzKVfj
For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com.
(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)